Skip to main content
SpringerLink
Log in

Epigenetics Involvement in Breast Cancer

  • Chapter
  • First Online:
Breast Cancer: From Bench to Personalized Medicine

  • 700 Accesses

Abstract

Breast cancer is the most common cancer among women worldwide, costing the lives of millions of women around the world. Despite the enormous research by scientists, screening programs, and awareness campaigns, we are still far away from the goal of lowering the global burden of breast cancer. For the precise drug designing and better clinical management of breast carcinoma, it is essential to decipher the underpinning molecular mechanisms of breast carcinogenesis. Due to enormous efforts to understand tumor biology, it had been unveiled that transformation of normal to malignant cells involves not only genetic mutations but also epigenetic mutations. The interplay of both types of mutations initiates malignant transformation and is responsible for cancer development and progression.

The distinguishing property of epigenetic mutations is that epigenetic modifications do not alter the sequence of the DNA, making them not only an attractive candidate as a prognostic and diagnostic biomarker but also a potential therapeutic target. Aberrant epigenetic modifications, namely, histone modifications, DNA methylation, and non-coding RNAs (ncRNAs) have a crucial role in initiating breast carcinogenesis, progression, and drug resistance. Moreover, distinct epigenetic mutations are involved in every stage of breast cancer and can be differentiated between the tumor and normal tissues. In this chapter, we will discuss in detail the three types of epigenetic modifications involved in breast cancer and will give a detailed account of their remarkable potential as diagnostic, prognostic, and predictive biomarkers. Lastly, we will also shed light on why epigenetic mutations hold a promising future as a therapeutic target for precision medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abdel-Hafiz HA, Horwitz KB (2015) Role of epigenetic modifications in luminal breast cancer. Epigenomics 7(5):847–862

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Agostini M, Enzo MV, Bedin C, Belardinelli V, Goldin E, Del Bianco P, Maschietto E, D’Angelo E, Izzi L, Saccani A, Zavagno G, Nitti D (2012) Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients. Cancer Biomark 11(2–3):89–98

    Article  CAS  PubMed  Google Scholar 

  • Antill YC, Mitchell G, Johnson SA, Devereux L, Milner A, Di Iulio J, Lindeman GJ, Kirk J, Phillips KA, Campbell IG (2010) Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomark Prev 19(1):265–274

    Article  CAS  Google Scholar 

  • Arun G, Diermeier S, Akerman M, Chang K-C, Wilkinson JE, Hearn S, Kim Y, MacLeod AR, Krainer AR, Norton L (2016) Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev 30(1):34–51

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Barata P, Sood AK, Hong DS (2016) RNA-targeted therapeutics in cancer clinical trials: current status and future directions. Cancer Treat Rev 50:35–47

    Article  CAS  PubMed  Google Scholar 

  • Barbano R, Muscarella LA, Pasculli B, Valori VM, Fontana A, Coco M, la Torre A, Balsamo T, Poeta ML, Marangi GF, Maiello E, Castelvetere M, Pellegrini F, Murgo R, Fazio VM, Parrella P (2013) Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics 8(1):105–112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Benevolenskaya EV, Islam AB, Ahsan H, Kibriya MG, Jasmine F, Wolff B, Al-Alem U, Wiley E, Kajdacsy-Balla A, Macias V, Rauscher GH (2016) DNA methylation and hormone receptor status in breast cancer. Clin Epigenetics 8(1):17

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Bennett RL, Licht JD (2018) Targeting epigenetics in cancer. Annu Rev Pharmacol Toxicol 58:187–207

    Article  CAS  PubMed  Google Scholar 

  • Berteaux N, Aptel N, Cathala G, Genton C, Coll J, Daccache A, Spruyt N, Hondermarck H, Dugimont T, Curgy JJ, Forne T, Adriaenssens E (2008) A novel H19 antisense RNA overexpressed in breast cancer contributes to paternal IGF2 expression. Mol Cell Biol 28(22):6731–6745

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bird A (2007) Perceptions of epigenetics. Nature 447(7143):396–398

    Article  CAS  PubMed  Google Scholar 

  • Boettcher M, Kischkel F, Hoheisel JD (2010) High-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistance. PLoS One 5(6):e11002

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Braunstein M, Liao L, Lyttle N, Lobo N, Taylor KJ, Krzyzanowski PM, Kalatskaya I, Yao CQ, Stein LD, Boutros PC (2016) Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer. Breast Cancer Res 18(1):1–16

    Article  CAS  Google Scholar 

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

    Article  PubMed  Google Scholar 

  • Breitbach S, Tug S, Simon P (2012) Circulating cell-free DNA: an up-coming molecular marker in exercise physiology. Sports Med 42(7):565–586

    Article  PubMed  Google Scholar 

  • Cai F-F, Chen S, Wang M-H, Lin X-Y, Zhang L, Zhang J-X, Wang L-X, Yang J, Ding J-H, Pan X (2016) Pyrosequencing quantified methylation level of BRCA1 promoter as prognostic factor for survival in breast cancer patient. Oncotarget 7(19):27499

    Article  PubMed  PubMed Central  Google Scholar 

  • Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga J-Y, Brain E, Causeret S, DeLorenzi M (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717–729

    Article  CAS  PubMed  Google Scholar 

  • Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios C, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso M (2017) 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3). Breast 31:244–259

    Article  CAS  PubMed  Google Scholar 

  • Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, Tan PH, Ho GH, Lee AS (2013) Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res 19(16):4477–4487

    Article  CAS  PubMed  Google Scholar 

  • Chandra Gupta S, Nandan Tripathi Y (2017) Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets. Int J Cancer 140(9):1955–1967

    Article  CAS  PubMed  Google Scholar 

  • Chang HG, Kim SJ, Chung K-W, Noh D-Y, Kwon Y, Lee ES, Kang H-S (2005) Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor β but not the estrogen receptor α gene. J Mol Med 83(2):132–139

    Article  CAS  PubMed  Google Scholar 

  • Cheetham SW, Gruhl F, Mattick JS, Dinger ME (2013) Long noncoding RNAs and the genetics of cancer. Br J Cancer 108(12):2419–2425

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen J, Miao Z, Xue B, Shan Y, Weng G, Shen B (2016) Long non-coding RNAs in urologic malignancies: functional roles and clinical translation. Cancer 7(13):1842–1855

    Article  CAS  Google Scholar 

  • Chen QF, Huang T, Si-Tu QJ, Wu P, Shen L, Li W, Huang Z (2020) Analysis of competing endogenous RNA network identifies a poorly differentiated cancer-specific RNA signature for hepatocellular carcinoma. Cell Biochem 121(3):2303–2317

    Article  CAS  Google Scholar 

  • Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn H-J, Members P, André F (2015a) Tailoring therapies—improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26(8):1533–1546

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn H-J, Members P, André F (2015b) Tailoring therapies—improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. J Ann Oncol 26(8):1533–1546

    Article  CAS  Google Scholar 

  • Costa-Pinheiro P, Montezuma D, Henrique R, Jeronimo C (2015) Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics 7(6):1003–1015

    Article  CAS  PubMed  Google Scholar 

  • Damaskos C, Garmpis N, Valsami S, Kontos M, Spartalis E, Kalampokas T, Kalampokas E, Athanasiou A, Moris D, Daskalopoulou A, Davakis S, Tsourouflis G, Kontzoglou K, Perrea D, Nikiteas N, Dimitroulis D (2017) Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer. Anticancer Res 37(1):35–46

    Article  CAS  PubMed  Google Scholar 

  • Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150(1):12–27

    Article  CAS  PubMed  Google Scholar 

  • De La Taille A (2007) Progensa™ pca3 test for prostate cancer detection. Expert Rev Mol Diagn 7(5):491–497

    Article  PubMed  Google Scholar 

  • Deaton AM, Bird A (2011) CpG islands and the regulation of transcription. Genes Dev 25(10):1010–1022

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Telli ML, Trudeau ME (2016) Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)–negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology guideline adaptation of the Cancer Care Ontario clinical practice guideline. J Clin Oncol 34(20):2416–2427

    Article  CAS  PubMed  Google Scholar 

  • Deng LL, Chi YY, Liu L, Huang NS, Wang L, Wu J (2016) LINC00978 predicts poor prognosis in breast cancer patients. Sci Rep 6(1):37936

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Di Leva G, Garofalo M, Croce CM (2014) MicroRNAs in cancer. Annu Rev Pathol 9:287–314

    Article  PubMed  CAS  Google Scholar 

  • Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, Xue C, Marinov GK, Khatun J, Williams BA, Zaleski C, Rozowsky J, Roder M, Kokocinski F, Abdelhamid RF, Alioto T, Antoshechkin I, Baer MT, Bar NS, Batut P, Bell K, Bell I, Chakrabortty S, Chen X, Chrast J, Curado J, Derrien T, Drenkow J, Dumais E, Dumais J, Duttagupta R, Falconnet E, Fastuca M, Fejes-Toth K, Ferreira P, Foissac S, Fullwood MJ, Gao H, Gonzalez D, Gordon A, Gunawardena H, Howald C, Jha S, Johnson R, Kapranov P, King B, Kingswood C, Luo OJ, Park E, Persaud K, Preall JB, Ribeca P, Risk B, Robyr D, Sammeth M, Schaffer L, See LH, Shahab A, Skancke J, Suzuki AM, Takahashi H, Tilgner H, Trout D, Walters N, Wang H, Wrobel J, Yu Y, Ruan X, Hayashizaki Y, Harrow J, Gerstein M, Hubbard T, Reymond A, Antonarakis SE, Hannon G, Giddings MC, Ruan Y, Wold B, Carninci P, Guigo R, Gingeras TR (2012) Landscape of transcription in human cells. Nature 489(7414):101–108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Downs B, Wang SM (2015) Epigenetic changes in BRCA1-mutated familial breast cancer. Cancer Genet 208(5):237–240

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dowsett M, Forbes J, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes R, Cuzick J, Early Breast Cancer Trialists’ Collaborative Group (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341–1352

    Article  CAS  Google Scholar 

  • Duffy SW, Mackay J, Thomas S, Anderson E, Chen TH, Ellis I, Evans G, Fielder H, Fox R, Gui G, Macmillan D, Moss S, Rogers C, Sibbering M, Wallis M, Warren R, Watson E, Whynes D, Allgood P, Caunt J (2013) Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study. Health Technol Assess 17(11):vii–xiv, 1–95

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717

    Article  CAS  Google Scholar 

  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 379(9814):432–444

    Article  CAS  Google Scholar 

  • Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18(7):1414

    Article  PubMed Central  CAS  Google Scholar 

  • Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA, Grainge MJ, Ball GR, Abdelghany MK, Martinez-Pomares L, Heery DM, Ellis IO (2009) Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 69(9):3802–3809

    Article  CAS  PubMed  Google Scholar 

  • Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92(7):564–569

    Article  CAS  PubMed  Google Scholar 

  • Fabian CJ, Kimler BF, Mayo MS, Khan SA (2005) Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 12(2):185–213

    Article  CAS  PubMed  Google Scholar 

  • Fiegl H, Millinger S, Goebel G, Muller-Holzner E, Marth C, Laird PW, Widschwendter M (2006) Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res 66(1):29–33

    Article  CAS  PubMed  Google Scholar 

  • Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89(22):1673–1682

    Article  CAS  PubMed  Google Scholar 

  • Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH (2008) Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283(2):1026–1033

    Article  CAS  PubMed  Google Scholar 

  • Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW (2016) Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget 7(7):7390–7402

    Article  PubMed  PubMed Central  Google Scholar 

  • Gao Y, Jones A, Fasching PA, Ruebner M, Beckmann MW, Widschwendter M, Teschendorff AE (2015) The integrative epigenomic-transcriptomic landscape of ER positive breast cancer. Clin Epigenetics 7(1):126

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Garmpis N, Damaskos C, Garmpi A, Kalampokas E, Kalampokas T, Spartalis E, Daskalopoulou A, Valsami S, Kontos M, Nonni A (2017) Histone deacetylases as new therapeutic targets in triple-negative breast cancer: progress and promises. Cancer Genomics Proteomics 14(5):299–313

    CAS  PubMed  PubMed Central  Google Scholar 

  • Gasparini P, Lovat F, Fassan M, Casadei L, Cascione L, Jacob NK, Carasi S, Palmieri D, Costinean S, Shapiro CL (2014) Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci U S A 111(12):4536–4541

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Geraldine O, Wang L, Zlott J, Juwara L, Covey JM, Beumer JH, Cristea MC, Newman EM, Koehler S, Nieva J (2020) Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. Cancer Chemother Pharmacol 85(5):979–993

    Article  CAS  Google Scholar 

  • Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN (2017) Breast cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(4):290–303

    Article  PubMed  Google Scholar 

  • Gomez-Moreno C (2009) New roles of flavoproteins in molecular cell biology. FEBS J 276(16):4289

    Article  CAS  PubMed  Google Scholar 

  • Gormally E, Caboux E, Vineis P, Hainaut P (2007) Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. J Mutat Res 635(2–3):105–117

    Article  CAS  Google Scholar 

  • Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R (2017) NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Cancer Netw 15(4):433–451

    Article  Google Scholar 

  • Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10(5):593–601

    Article  CAS  PubMed  Google Scholar 

  • Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, Morris M, Wyatt L, Farshid G, Lim YY, Lindeman GJ, Shannon MF, Drew PA, Khew-Goodall Y, Goodall GJ (2011) An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 22(10):1686–1698

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Griess B, Klinkebiel D, Kueh A, Desler M, Cowan K, Fitzgerald M, Teoh-Fitzgerald M (2020) Association ofSOD3 promoter DNA methylation with its down-regulation in breast carcinomas. Epigenetics 15(12):1325–1335

    Article  PubMed  PubMed Central  Google Scholar 

  • Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumar S, Chang HY (2010) Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464(7291):1071–1076

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Guttman M, Rinn JL (2012) Modular regulatory principles of large non-coding RNAs. Nature 482(7385):339–346

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Győrffy B, Bottai G, Fleischer T, Munkácsy G, Budczies J, Paladini L, Børresen-Dale AL, Kristensen VN, Santarpia L (2016) Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. Int J Cancer 138(1):87–97

    Article  PubMed  CAS  Google Scholar 

  • Haber DA, Velculescu VE (2014) Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 4(6):650–661

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A (2008) Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 26(31):5036–5042

    Article  CAS  PubMed  Google Scholar 

  • Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG (2016) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 34(10):1134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. J Ann Surg 251(3):499–505

    Article  Google Scholar 

  • Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349(21):2042–2054

    Article  CAS  PubMed  Google Scholar 

  • Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jonsson G, Olsson H, Borg A, Ringner M (2010) Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 12(3):R36

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Hua S, Kallen CB, Dhar R, Baquero MT, Mason CE, Russell BA, Shah PK, Liu J, Khramtsov A, Tretiakova MS, Krausz TN, Olopade OI, Rimm DL, White KP (2008) Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol 4(1):188

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Huarte M (2015) The emerging role of lncRNAs in cancer. Nat Med 21(11):1253–1261

    Article  CAS  PubMed  Google Scholar 

  • Hudis CA (2015) Biology before anatomy in early breast cancer—precisely the point. Massachusetts Medical Society, Waltham

    Book  Google Scholar 

  • Hur K, Cejas P, Feliu J, Moreno-Rubio J, Burgos E, Boland CR, Goel A (2014) Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut 63(4):635–646

    Article  CAS  PubMed  Google Scholar 

  • Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Menard S, Croce CM, Tagliabue E (2009) microRNA-205 regulates HER3 in human breast cancer. Cancer Res 69(6):2195–2200

    Article  CAS  PubMed  Google Scholar 

  • Jackson PE, Qian GS, Friesen MD, Zhu YR, Lu P, Wang JB, Wu Y, Kensler TW, Vogelstein B, Groopman JD (2001) Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res 61(1):33–35

    CAS  PubMed  Google Scholar 

  • Jansen MP, Reijm EA, Sieuwerts AM, Ruigrok-Ritstier K, Look MP, Rodriguez-Gonzalez FG, Heine AA, Martens JW, Sleijfer S, Foekens JA, Berns EM (2012) High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat 133(3):937–947

    Article  CAS  PubMed  Google Scholar 

  • Jiang S, Zhang H-W, Lu M-H, He X-H, Li Y, Gu H, Liu M-F, Wang E-D (2010) MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 70(8):3119–3127

    Article  CAS  PubMed  Google Scholar 

  • Jiang S, Zhang LF, Zhang HW, Hu S, Lu MH, Liang S, Li B, Li Y, Li D, Wang ED, Liu MF (2012) A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J 31(8):1985–1998

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jin P, Han TH, Ren J, Saunders S, Wang E, Marincola FM, Stroncek DF (2010) Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med 8(1):4

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Jones PA (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13(7):484–492

    Article  CAS  PubMed  Google Scholar 

  • Joo JE, Dowty JG, Milne RL, Wong EM, Dugue PA, English D, Hopper JL, Goldgar DE, Giles GG, Southey MC, kConFab (2018) Heritable DNA methylation marks associated with susceptibility to breast cancer. Nat Commun 9(1):867

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC Jr, Park ST, Pusztai L, Calin GA (2012) Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118(10):2603–2614

    Article  CAS  PubMed  Google Scholar 

  • Kamińska K, Nalejska E, Kubiak M, Wojtysiak J, Żołna Ł, Kowalewski J, Lewandowska MA (2019) Prognostic and predictive epigenetic biomarkers in oncology. Mol Diagn Ther 23(1):83–95

    Article  PubMed  CAS  Google Scholar 

  • Kavarthapu R, Morris C-HT, Dufau ML (2014) Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ERα and STAT5. Oncotarget 5(19):9079

    Article  PubMed  PubMed Central  Google Scholar 

  • Khew-Goodall Y, Goodall GJ (2012) A microRNA that limits metastatic colonisation and endothelial recruitment. EMBO J 31(4):786–787

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kilinc AN, Sugiyama N, Kalathur RKR, Antoniadis H, Birogul H, Ishay-Ronen D, George JT, Levine H, Jolly MK, Christofori G (2020) Histone deacetylases, Mbd3/NuRD, and Tet2 hydroxylase are crucial regulators of epithelial–mesenchymal plasticity and tumor metastasis. Oncogenesis 39(7):1498–1513

    Article  CAS  Google Scholar 

  • Kim J-H, Shin M-H, Kweon S-S, Park MH, Yoon JH, Lee JS, Choi C, Fackler MJ, Sukumar S (2010) Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women. Gynecol Oncol 118(2):176–181

    Article  CAS  PubMed  Google Scholar 

  • Kurihara Y, Kawamura Y, Uchijima Y, Amamo T, Kobayashi H, Asano T, Kurihara H (2008) Maintenance of genomic methylation patterns during preimplantation development requires the somatic form of DNA methyltransferase 1. Dev Biol 313(1):335–346

    Article  CAS  PubMed  Google Scholar 

  • Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T (2016) Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 17(11):1579–1589

    Article  CAS  PubMed  Google Scholar 

  • Leick MB, Shoff CJ, Wang EC, Congress JL, Gallicano GI (2012) Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer. Am J Stem Cells 1(1):59–74

    CAS  PubMed  Google Scholar 

  • Li J, Li X, Kong X, Luo Q, Zhang J, Fang L (2014a) MiRNA-26b inhibits cellular proliferation by targeting CDK8 in breast cancer. Int J Clin Exp Med 7(3):558–565

    PubMed  PubMed Central  Google Scholar 

  • Li XY, Luo QF, Wei CK, Li DF, Li J, Fang L (2014b) MiRNA-107 inhibits proliferation and migration by targeting CDK8 in breast cancer. Int J Clin Exp Med 7(1):32–40

    PubMed  PubMed Central  Google Scholar 

  • Li Y, Zhang Y, Li S, Lu J, Chen J, Wang Y, Li Y, Xu J, Li X (2015) Genome-wide DNA methylome analysis reveals epigenetically dysregulated non-coding RNAs in human breast cancer. Sci Rep 5(1):8790

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li A, Liu Z, Li M, Zhou S, Xu Y, Xiao Y, Yang W (2016) HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer. Oncotarget 7(25):37966–37978

    Article  PubMed  PubMed Central  Google Scholar 

  • Lim S, Janzer A, Becker A, Zimmer A, Schüle R, Buettner R, Kirfel J (2010) Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 31(3):512–520

    Article  CAS  PubMed  Google Scholar 

  • Liu L, Sun L, Li C, Li X, Zhang Y, Yu Y, Xia W (2015) Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients. Biomed Mater Eng 26 Suppl 1(s1):S2217–S2222

    Google Scholar 

  • Liu Y, Jin X, Li Y, Ruan Y, Lu Y, Yang M, Lin D, Song P, Guo Y, Zhao S, Dong B, Xie Y, Dang Q, Quan C (2016a) DNA methylation of claudin-6 promotes breast cancer cell migration and invasion by recruiting MeCP2 and deacetylating H3Ac and H4Ac. Exp Clin Cancer Res 35(1):120

    Article  CAS  Google Scholar 

  • Liu H, Li J, Koirala P, Ding X, Chen B, Wang Y, Wang Z, Wang C, Zhang X, Mo Y-Y (2016b) Long non-coding RNAs as prognostic markers in human breast cancer. Oncotarget 7(15):20584

    Article  PubMed  PubMed Central  Google Scholar 

  • Liu F, Ma F, Wang Y, Hao L, Zeng H, Jia C, Wang Y, Liu P, Ong IM, Li B (2017) PKM2 methylation by CARM1 activates aerobic glycolysis to promote tumorigenesis. Nat Cell Biol 19(11):1358–1370

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lo YM (2000) Fetal DNA in maternal plasma: biology and diagnostic applications. Clin Chem 46(12):1903–1906

    Article  CAS  PubMed  Google Scholar 

  • Lord CJ, Ashworth A (2016) BRCAness revisited. Nat Rev Cancer 16(2):110–120

    Article  CAS  PubMed  Google Scholar 

  • Lorincz AT (2011) The promise and the problems of epigenetic biomarkers in cancer. Expert Opin Med Diag 5(5):375–379

    Article  CAS  Google Scholar 

  • Lyko F (2018) The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet 19(2):81–92

    Article  CAS  PubMed  Google Scholar 

  • Ma L (2010a) Role of miR-10b in breast cancer metastasis. Breast Cancer Res 12(5):210

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ma L (2010b) Role of miR-10b in breast cancer metastasis. Breast Cancer Res 12(5):1–5

    Article  CAS  Google Scholar 

  • Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163):682–688

    Article  CAS  PubMed  Google Scholar 

  • Ma Y, Wang X, Jin H (2013) Methylated DNA and microRNA in body fluids as biomarkers for cancer detection. Int J Mol Sci 14(5):10307–10331

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Magee P, Shi L, Garofalo M (2015) Role of microRNAs in chemoresistance. Ann Transl Med 3(21):332

    PubMed  PubMed Central  Google Scholar 

  • Marie-Hélene Quentien VV, Menasche M, Dufier J-L, Herman J-P, Enjalbert A, Abitbol M, Brue T (2011) Truncation of PITX2 differentially affects its activity on physiological targets. J Mol Endocrinol 46:9–19

    Article  PubMed  CAS  Google Scholar 

  • Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, Meijer-Van Gelder ME, Piepenbrock C, Olek A, Hofler H, Kiechle M, Klijn JG, Schmitt M, Maier S, Foekens JA (2005) Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 65(10):4101–4117

    Article  CAS  PubMed  Google Scholar 

  • McDermott AM, Miller N, Wall D, Martyn LM, Ball G, Sweeney KJ, Kerin MJ (2014) Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. PLoS One 9(1):e87032

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Meeran SM, Ahmed A, Tollefsbol TO (2010) Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenetics 1(3–4):101–116

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Meng Z, Liu Y, Wang J, Fan H, Fang H, Li S, Yuan L, Liu C, Peng Y, Zhao W (2020) Histone demethylase KDM7A is required for stem cell maintenance and apoptosis inhibition in breast cancer. J Cell Physiol 235(2):932–943

    Article  CAS  PubMed  Google Scholar 

  • Meseure D, Vacher S, Lallemand F, Alsibai KD, Hatem R, Chemlali W, Nicolas A, De Koning L, Pasmant E, Callens C, Lidereau R, Morillon A, Bieche I (2016) Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer. Br J Cancer 114(12):1395–1404

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Moss S (2004) Should women under 50 be screened for breast cancer? Br J Cancer 91(3):413–417

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Müller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, Winzer K-J, Dietel M, Weichert W, Denkert C (2013) Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 13(1):1–8

    Article  CAS  Google Scholar 

  • Müller O, Kepper N, Schöpflin R, Ettig R, Rippe K, Wedemann G (2014) Changing chromatin fiber conformation by nucleosome repositioning. Biophys J 107(9):2141–2150

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Mulrane L, Madden SF, Brennan DJ, Gremel G, McGee SF, McNally S, Martin F, Crown JP, Jirström K, Higgins DG (2012) miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro. J Clin Cancer Res 18(24):6702–6713

    Article  CAS  Google Scholar 

  • Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104(12):1828–1835

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nagelkerke A, van Kuijk SJ, Sweep FC, Nagtegaal ID, Hoogerbrugge N, Martens JW, Timmermans MA, van Laarhoven HW, Bussink J, Span PNJR (2011) Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer. Radiother Oncol 101(1):39–45

    Article  CAS  PubMed  Google Scholar 

  • Nettles KW, Gil G, Nowak J, Métivier R, Sharma VB, Greene GL (2008) CBP is a dosage-dependent regulator of nuclear factor-κB suppression by the estrogen receptor. Mol Endocrinol 22(2):263–272

    Article  CAS  PubMed  Google Scholar 

  • Network NCC (2017) Breast cancer screening and diagnosis. Clinical practice guidelines in oncology 1

    Google Scholar 

  • Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH (2015) A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol 75(3):537–546

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nguyen C, Liang G, Nguyen TT, Tsao-Wei D, Groshen S, Lubbert M, Zhou JH, Benedict WF, Jones PA (2001) Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst 93(19):1465–1472

    Article  CAS  PubMed  Google Scholar 

  • Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D (2008) DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat 111(3):429–437

    Article  CAS  PubMed  Google Scholar 

  • Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. Clin Oncol 23(12):2716–2725

    Google Scholar 

  • Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846

    Article  PubMed  PubMed Central  Google Scholar 

  • Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM (2000) CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci U S A 97(3):1020–1025

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22(7):894–907

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Parrella P, Barbano R, Pasculli B, Fontana A, Copetti M, Valori VM, Poeta ML, Perrone G, Righi D, Castelvetere M, Coco M, Balsamo T, Morritti M, Pellegrini F, Onetti-Muda A, Maiello E, Murgo R, Fazio VM (2014) Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients. Mol Cancer 13(1):142

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Pasculli B, Barbano R, Parrella P (2018) Epigenetics of breast cancer: biology and clinical implication in the era of precision medicine. In: Seminars in cancer biology, Elsevier

    Google Scholar 

  • PDQ Supportive and Palliative Care Editorial Board (2015). Adjustment to cancer: anxiety and distress (PDQ®). PDQ cancer information summaries

    Google Scholar 

  • Peto R, Davies C, Godwin J, Gray R, Pan H, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Early Breast Cancer Trialists’ Collaborative Group (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444

    Article  CAS  PubMed  Google Scholar 

  • Png KJ, Halberg N, Yoshida M, Tavazoie SF (2012) A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nat Rev Cancer 481(7380):190–194

    CAS  Google Scholar 

  • Ponnusamy L, Mahalingaiah PKS, Chang YW, Singh KP (2018) Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells. Eur J Pharm Sci 123:56–69

    Article  CAS  PubMed  Google Scholar 

  • Pronina IV, Loginov VI, Burdennyy AM, Fridman MV, Senchenko VN, Kazubskaya TP, Kushlinskii NE, Dmitriev AA, Braga EA (2017) DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. Gene 604:1–8

    Article  CAS  PubMed  Google Scholar 

  • Qaseem A, Snow V, Sherif K, Aronson M, Weiss KB, Owens DK, Clinical Efficacy Assessment Subcommittee of the American College of Physicians (2007) Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med 146(7):511–515

    Article  PubMed  Google Scholar 

  • Radpour R, Barekati Z, Kohler C, Lv Q, Burki N, Diesch C, Bitzer J, Zheng H, Schmid S, Zhong XY (2011) Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One 6(1):e16080

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Raveh E, Matouk IJ, Gilon M, Hochberg A (2015) The H19 long non-coding RNA in cancer initiation, progression and metastasis–a proposed unifying theory. Mol Cancer 14(1):1–14

    Article  CAS  Google Scholar 

  • Redis RS, Sieuwerts AM, Look MP, Tudoran O, Ivan C, Spizzo R, Zhang X, de Weerd V, Shimizu M, Ling H, Buiga R, Pop V, Irimie A, Fodde R, Bedrosian I, Martens JW, Foekens JA, Berindan-Neagoe I, Calin GA (2013) CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget 4(10):1748–1762

    Article  PubMed  PubMed Central  Google Scholar 

  • Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E, Chang HY (2007) Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 129(7):1311–1323

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Roberti A, Valdes AF, Torrecillas R, Fraga MF, Fernandez AF (2019) Epigenetics in cancer therapy and nanomedicine. Clin Epigenetics 11(1):81

    Article  PubMed  PubMed Central  Google Scholar 

  • Robertson KD (2001) DNA methylation, methyltransferases, and cancer. Oncogene 20(24):3139–3155

    Article  CAS  PubMed  Google Scholar 

  • Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6(8):597–610

    Article  CAS  PubMed  Google Scholar 

  • Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523–533

    Article  CAS  PubMed  Google Scholar 

  • Rodríguez-González FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, Martens JW, Foekens JA (2011) MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 127(1):43–51

    Article  PubMed  CAS  Google Scholar 

  • Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H (2010) Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 12(6):1–8

    Article  CAS  Google Scholar 

  • Salas LA, Lundgren SN, Browne EP, Punska EC, Anderton DL, Karagas MR, Arcaro KF, Christensen BC (2020) Prediagnostic breast milk DNA methylation alterations in women who develop breast cancer. Hum Mol Genet 29(4):662–673

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Salta S, Nunes SP, Fontes-Sousa M, Lopes P, Freitas M, Caldas M, Antunes L, Castro F, Antunes P, de Sousa SP, Henrique R, Jeronimo C (2018) A DNA methylation-based test for breast cancer detection in circulating cell-free DNA. Clin Med 7(11):420

    CAS  Google Scholar 

  • Saxena M, Kalathur RK, Rubinstein N, Vettiger A, Sugiyama N, Neutzner M, Coto-Llerena M, Kancherla V, Ercan C, Piscuoglio S (2020) A Pygopus 2-histone interaction is critical for cancer cell dedifferentiation and progression in malignant breast cancer. Cancer Res 80(17):3631–3648

    Article  CAS  PubMed  Google Scholar 

  • Schricker G, Napieralski R, Noske A, Piednoir E, Manner O, Schuren E, Lauber J, Perkins J, Magdolen V, Schmitt M, Ulm K, Weichert W, Kiechle M, Martens JWM, Wilhelm OG (2018) Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer. Sci Rep 8(1):16861

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Schwarzenbach H, Nishida N, Calin GA, Pantel K (2014) Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 11(3):145–156

    Article  CAS  PubMed  Google Scholar 

  • Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F, Committee EG (2015) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v8–v30

    Article  PubMed  Google Scholar 

  • Serce N, Gnatzy A, Steiner S, Lorenzen H, Kirfel J, Buettner R (2012) Elevated expression of LSD1 (lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. BMC Clin Pathol 12(1):13

    Article  PubMed  PubMed Central  Google Scholar 

  • Severi G, Southey MC, English DR, Jung C-H, Lonie A, McLean C, Tsimiklis H, Hopper JL, Giles GG, Baglietto L (2014) Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer. Breast Cancer Res Treat 148(3):665–673

    Article  CAS  PubMed  Google Scholar 

  • Shan M, Yin H, Li J, Li X, Wang D, Su Y, Niu M, Zhong Z, Wang J, Zhang X, Kang W, Pang D (2016) Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer. Oncotarget 7(14):18485–18494

    Article  PubMed  PubMed Central  Google Scholar 

  • Shen Y, Katsaros D, Loo LW, Hernandez BY, Chong C, Canuto EM, Biglia N, Lu L, Risch H, Chu WM, Yu H (2015) Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer. Oncotarget 6(11):8579–8592

    Article  PubMed  PubMed Central  Google Scholar 

  • Sher G, Salman NA, Khan AQ, Prabhu KS, Raza A, Kulinski M, Dermime S, Haris M, Junejo K, Uddin S (2020) Epigenetic and breast cancer therapy: promising diagnostic and therapeutic applications. In: Seminars in cancer biology, Elsevier

    Google Scholar 

  • Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, Hui AB, Sykes J, P'ng C, Miller N, McCready D, Fyles A, Liu FF (2011) MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res 71(8):2926–2937

    Article  CAS  PubMed  Google Scholar 

  • Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ (2015) LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget 6(13):11652–11663

    Article  PubMed  PubMed Central  Google Scholar 

  • Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY (2007) miR-21-mediated tumor growth. Oncogene 26(19):2799–2803

    Article  CAS  PubMed  Google Scholar 

  • Siegal R, Miller K, Jemal A (2014) Cancer statistics, 2012. CA Cancer J Clin 64(1):9–29

    Google Scholar 

  • Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Wender RC (2019) Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 69(3):184–210

    Article  PubMed  Google Scholar 

  • Sørensen KP, Thomassen M, Tan Q, Bak M, Cold S, Burton M, Larsen MJ, Kruse TA (2013) Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer. Breast Cancer Res 142(3):529–536

    Article  CAS  Google Scholar 

  • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111–121

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Swellam M, Abdelmaksoud MD, Sayed Mahmoud M, Ramadan A, Abdel-Moneem W, Hefny MM (2015) Aberrant methylation of APC and RARβ2 genes in breast cancer patients. IUBMB Life 67(1):61–68

    Article  CAS  PubMed  Google Scholar 

  • Swygert SG, Peterson CL (2014) Chromatin dynamics: interplay between remodeling enzymes and histone modifications. J Biochim Biophys Acta 1839(8):728–736

    Article  CAS  Google Scholar 

  • Tang Q, Cheng J, Cao X, Surowy H, Burwinkel B (2016) Blood-based DNA methylation as biomarker for breast cancer: a systematic review. J Clin Epigenet 8(1):1–18

    CAS  Google Scholar 

  • Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massagué J (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nat Rev Cancer 451(7175):147–152

    CAS  Google Scholar 

  • Thomas ML, Marcato P (2018) Epigenetic modifications as biomarkers of tumor development, therapy response, and recurrence across the cancer care continuum. Cancers 10(4):101

    Article  PubMed Central  CAS  Google Scholar 

  • Tong YK, Lo YM (2006) Diagnostic developments involving cell-free (circulating) nucleic acids. Clin Chim Acta 363(1–2):187–196

    Article  CAS  PubMed  Google Scholar 

  • Tryndyak VP, Beland FA, Pogribny IP (2010) E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 126(11):2575–2583

    CAS  PubMed  Google Scholar 

  • Tweedie-Cullen RY, Brunner AM, Grossmann J, Mohanna S, Sichau D, Nanni P, Panse C, Mansuy IM (2012) Identification of combinatorial patterns of post-translational modifications on individual histones in the mouse brain. PLoS One 7(5):e36980

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ushijima T, Asada K (2010) Aberrant DNA methylation in contrast with mutations. Cancer Sci 101(2):300–305

    Article  CAS  PubMed  Google Scholar 

  • Van De Voorde L, Speeckaert R, Van Gestel D, Bracke M, De Neve W, Delanghe J, Speeckaert M (2012) DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat Res 751(2):304–325

    Article  CAS  Google Scholar 

  • Van Grembergen O, Bizet M, de Bony EJ, Calonne E, Putmans P, Brohee S, Olsen C, Guo M, Bontempi G, Sotiriou C, Defrance M, Fuks F (2016) Portraying breast cancers with long noncoding RNAs. Sci Adv 2(9):e1600220

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W (2015) Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 33(24):2695

    Article  PubMed  PubMed Central  Google Scholar 

  • Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103(7):2257–2261

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang Z, Schones DE, Zhao K (2009) Characterization of human epigenomes. Curr Opin Genet Dev 19(2):127–134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang F, Zheng Z, Guo J, Ding X (2010) Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 119(3):586–593

    Article  CAS  PubMed  Google Scholar 

  • Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, Luo H (2012) Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 7(4):e34210

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang X, Zhang W, Tang J, Huang R, Li J, Xu D, Xie Y, Jiang R, Deng L, Zhang X, Chai Y, Qin X, Sun B (2016) LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway. Cell Death Dis 7(3):e2130

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang Y, Zeng J, Wu W, Xie S, Yu H, Li G, Zhu T, Li F, Lu J, Wang GY (2019) Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization. Breast Cancer Res 21(1):1–17

    Article  Google Scholar 

  • Wilting RH, Dannenberg JH (2012) Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat 15(1–2):21–38

    Article  CAS  PubMed  Google Scholar 

  • Wishart GC, Bajdik CD, Azzato EM, Dicks E, Greenberg DC, Rashbass J, Caldas C, Pharoah PD (2011) A population-based validation of the prognostic model PREDICT for early breast cancer. Eur J Surg Oncol 37(5):411–417

    Article  CAS  PubMed  Google Scholar 

  • Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, Giles GG, Hopper JL, Dobrovic A (2011) Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res 4(1):23–33

    Article  CAS  Google Scholar 

  • Xiang TX, Yuan Y, Li LL, Wang ZH, Dan LY, Chen Y, Ren GS, Tao Q (2013) Aberrant promoter CpG methylation and its translational applications in breast cancer. Chin J Cancer 32(1):12–20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xu Y, Diao L, Chen Y, Liu Y, Wang C, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Deng D, Narod SA, Xie Y (2013) Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. Ann Oncol 24(6):1498–1505

    Article  CAS  PubMed  Google Scholar 

  • Xu N, Chen F, Wang F, Lu X, Wang X, Lv M, Lu C (2015) Clinical significance of high expression of circulating serum lncRNA RP11-445H22.4 in breast cancer patients: a Chinese population-based study. Tumour Biol 36(10):7659–7665

    Article  CAS  PubMed  Google Scholar 

  • Yamada T, Nakamori S, Ohzato H, Oshima S, Aoki T, Higaki N, Sugimoto K, Akagi K, Fujiwara Y, Nishisho I, Sakon M, Gotoh M, Monden M (1998) Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res 4(6):1527–1532

    CAS  PubMed  Google Scholar 

  • Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F, Leu YW, Shapiro CL, Eng C, Yeatman TJ, Huang TH (2006) Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 12(22):6626–6636

    Article  CAS  PubMed  Google Scholar 

  • Yang R, Pfutze K, Zucknick M, Sutter C, Wappenschmidt B, Marme F, Qu B, Cuk K, Engel C, Schott S, Schneeweiss A, Brenner H, Claus R, Plass C, Bugert P, Hoth M, Sohn C, Schmutzler R, Bartram CR, Burwinkel B (2015) DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood. Int J Cancer 136(8):1845–1855

    Article  CAS  PubMed  Google Scholar 

  • Zhang W, Xu J (2017) DNA methyltransferases and their roles in tumorigenesis. J Biomark Res 5(1):1–8

    Article  Google Scholar 

  • Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, Mita K, Hamaguchi M, Hayashi S-I, Iwase H (2004) HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 10(20):6962–6968

    Article  CAS  PubMed  Google Scholar 

  • Zhang KJ, Tan XL, Guo L (2020) The long non-coding RNA DANCR regulates the inflammatory phenotype of breast cancer cells and promotes breast cancer progression via EZH2-dependent suppression of SOCS3 transcription. Mol Oncol 14(2):309–328

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Zhao R, Wu J, Jia W, Gong C, Yu F, Ren Z, Chen K, He J, Su F (2011) Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Oncol Res Treat 34(12):675–680

    CAS  Google Scholar 

  • Zhao W, Luo J, Jiao S (2014) Comprehensive characterization of cancer subtype associated long non-coding RNAs and their clinical implications. Sci Rep 4(1):1–7

    Google Scholar 

  • Zhu S, Si ML, Wu H, Mo YY (2007) MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). Biol Chem 282(19):14328–14336

    Article  CAS  Google Scholar 

  • Zhu W, Qin W, Atasoy U, Sauter ER (2009) Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2(1):89

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H, Gong C, Chen J, Su F, Zhang Y (2011) Reduced miR-128 in breast tumor–initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 17(22):7105–7115

    Article  CAS  PubMed  Google Scholar 

  • Zubor P, Kubatka P, Kajo K, Dankova Z, Polacek H, Bielik T, Kudela E, Samec M, Liskova A, Vlcakova D, Kulkovska T, Stastny I, Holubekova V, Bujnak J, Laucekova Z, Busselberg D, Adamek M, Kuhn W, Danko J, Golubnitschaja O (2019) Why the gold standard approach by mammography demands extension by multiomics? Application of liquid biopsy miRNA profiles to breast cancer disease management. Int J Mol Sci 20(12):2878

    Article  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Indus Hospital Research Center, Indus Hospital and Health Network, Karachi, Pakistan

    Mariam Ashfaq Khan

Authors
  1. Mariam Ashfaq Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Genetics, Research Division, The University of Alabama, Birmingham, AL, USA

    Saima Shakil Malik

  2. Department of Biotechnology, Fatima Jinnah Women University, Rawalpindi, Pakistan

    Nosheen Masood

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Khan, M.A. (2022). Epigenetics Involvement in Breast Cancer. In: Shakil Malik, S., Masood, N. (eds) Breast Cancer: From Bench to Personalized Medicine. Springer, Singapore. https://doi.org/10.1007/978-981-19-0197-3_8

Download citation

Publish with us

Policies and ethics

Search

Navigation